Immunotherapies targeting the PD-1/PD-L1 pathway have particularly proven effective in controlling tumor growth through the reinvigoration of CD8+ T cells and/or NK cells across numerous tumor settings, including oral cancer (30). The gene discussed is CD8A; the disease is lip and oral cavity carcinoma.